These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 12010328)

  • 1. Neo-adjuvant treatment of infiltrating transitional-cell carcinoma of the bladder with paclitaxel and cisplatin: a phase II trial.
    Sousa-Escandon A; Vazquez S; Quintero-Aldana G; Picallo JA; Neira J; Garcia-Novio F; Mateo A; Rico M; Mel JR
    Int J Urol; 2002 Mar; 9(3):162-6. PubMed ID: 12010328
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of patients with transitional-cell carcinoma of the urothelial tract with ifosfamide, paclitaxel, and cisplatin: a phase II trial.
    Bajorin DF; McCaffrey JA; Hilton S; Mazumdar M; Kelly WK; Scher HI; Spicer J; Herr H; Higgins G
    J Clin Oncol; 1998 Aug; 16(8):2722-7. PubMed ID: 9704723
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence for a schedule-dependent deleterious interaction between paclitaxel, vinblastine and cisplatin (PVC) in the treatment of advanced transitional cell carcinoma.
    Mulatero C; McClaren BR; Mason M; Oliver RT; Gallagher CJ
    Br J Cancer; 2000 Dec; 83(12):1612-6. PubMed ID: 11104554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules.
    Bajorin DF; McCaffrey JA; Dodd PM; Hilton S; Mazumdar M; Kelly WK; Herr H; Scher HI; Icasiano E; Higgins G
    Cancer; 2000 Apr; 88(7):1671-8. PubMed ID: 10738226
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I trial of paclitaxel, carboplatin, and methotrexate with granulocyte colony-stimulating factor and leucovorin in advanced transitional cell carcinoma.
    Edelman MJ; Meyers FJ; Houston J; Lauder I
    Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-68-S15-71. PubMed ID: 9346226
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell bladder carcinoma. A preliminary report of tolerance and local control.
    Varveris H; Delakas D; Anezinis P; Haldeopoulos D; Mazonakis M; Damilakis J; Metaxaris G; Chondros N; Mavromanolakis E; Daskalopoulos G; Dimitrakopoulos A; Kranidis A
    Anticancer Res; 1997; 17(6D):4771-80. PubMed ID: 9494605
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Final results of sequential doxorubicin plus gemcitabine and ifosfamide, paclitaxel, and cisplatin chemotherapy in patients with metastatic or locally advanced transitional cell carcinoma of the urothelium.
    Milowsky MI; Nanus DM; Maluf FC; Mironov S; Shi W; Iasonos A; Riches J; Regazzi A; Bajorin DF
    J Clin Oncol; 2009 Sep; 27(25):4062-7. PubMed ID: 19636012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemotherapy with cisplatin, epirubicin and docetaxel in transitional cell urothelial cancer. Phase II trial.
    Pectasides D; Visvikis A; Aspropotamitis A; Halikia A; Karvounis N; Dimitriadis M; Athanassiou A
    Eur J Cancer; 2000 Jan; 36(1):74-9. PubMed ID: 10741298
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination chemotherapy of cisplatin, methotrexate, vinblastine, and high-dose tamoxifen for transitional cell carcinoma.
    Hsu CH; Chen J; Wu CY; Cheng AL; Pu YS
    Anticancer Res; 2001; 21(1B):711-5. PubMed ID: 11299831
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RTOG 97-06: initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy.
    Hagan MP; Winter KA; Kaufman DS; Wajsman Z; Zietman AL; Heney NM; Toonkel LM; Jones CU; Roberts JD; Shipley WU
    Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):665-72. PubMed ID: 14529770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility trial of methotrexate-paclitaxel as a second line therapy in advanced urothelial cancer.
    Bellmunt J; Cos J; Clèries R; Pérez M; Ribas A; Eres N; Murio JE; Margarit C; Baselga J
    Cancer Invest; 2002; 20(5-6):673-85. PubMed ID: 12197223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of weekly paclitaxel, cisplatin plus infusional high dose 5-fluorouracil and leucovorin for metastatic urothelial carcinoma.
    Lin CC; Hsu CH; Huang CY; Cheng AL; Vogelzang NJ; Pu YS
    J Urol; 2007 Jan; 177(1):84-9; discussion 89. PubMed ID: 17162009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract.
    Uhm JE; Lim HY; Kim WS; Choi HY; Lee HM; Park BB; Park K; Kang WK
    Neoplasia; 2007 Jan; 9(1):18-22. PubMed ID: 17325740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of weekly paclitaxel plus 24-h continuous infusion 5-fluorouracil, folinic acid and 3-weekly cisplatin for the treatment of patients with advanced gastric cancer.
    Honecker F; Kollmannsberger C; Quietzsch D; Haag C; Schroeder M; Spott C; Hartmann JT; Baronius W; Hempel V; Kanz L; Bokemeyer C
    Anticancer Drugs; 2002 Jun; 13(5):497-503. PubMed ID: 12045461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weekly paclitaxel and gemcitabine in advanced transitional-cell carcinoma of the urothelium: a phase II Hoosier Oncology Group study.
    Li J; Juliar B; Yiannoutsos C; Ansari R; Fox E; Fisch MJ; Einhorn LH; Sweeney CJ
    J Clin Oncol; 2005 Feb; 23(6):1185-91. PubMed ID: 15718315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant activity of paclitaxel in advanced transitional-cell carcinoma of the urothelium: a phase II trial of the Eastern Cooperative Oncology Group.
    Roth BJ; Dreicer R; Einhorn LH; Neuberg D; Johnson DH; Smith JL; Hudes GR; Schultz SM; Loehrer PJ
    J Clin Oncol; 1994 Nov; 12(11):2264-70. PubMed ID: 7525883
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomised phase II trial of gemcitabine and paclitaxel second-line chemotherapy in patients with transitional cell carcinoma (AUO Trial AB 20/99).
    Fechner G; Siener R; Reimann M; Kobalz L; Albers P;
    Int J Clin Pract; 2006 Jan; 60(1):27-31. PubMed ID: 16409425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Methotrexate-paclitaxel-epirubicin-carboplatin (M-TEC) combination chemotherapy in patients with advanced bladder cancer: an open label phase II study.
    Tsavaris N; Kosmas C; Skopelitis H; Dimitrakopoulos A; Kopterides P; Bougas D; Stravodimos K; Mitropoulos D; Alamanis C; Giannopoulos A
    J Chemother; 2005 Aug; 17(4):441-8. PubMed ID: 16167525
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adverse events of MVAC chemotherapy in patients with advanced urothelial cancer of the bladder.
    Maeda T; Takahashi A; Hirobe M; Honma I; Masumori N; Itoh N; Tsukamoto T
    Hinyokika Kiyo; 2007 Apr; 53(4):213-9. PubMed ID: 17515069
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cisplatin-epirubicin-paclitaxel weekly administration in advanced breast cancer: a phase I study of the Southern Italy Cooperative Oncology Group.
    Frasci G; D'Aiuto G; Comella P; Apicella A; Thomas R; Capasso I; Di Bonito M; Cartenì G; Biglietto M; De Lucia L; Maiorino L; Piccolo S; Bianchi U; D'Aniello R; Lapenta L; Comella G
    Breast Cancer Res Treat; 1999 Aug; 56(3):239-52. PubMed ID: 10573115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.